Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Intransal oxytocin in the treatment of autism  

There is accumulating evidence that oxytocin, produced by the hypothalamus, plays a key role in social cognition and attachment, repetitive behaviors, and anxiety. Based on such data, abnormalities in the oxytocin system may be responsible for some of the core and associated deficits seen in autism. In this study, intranasal oxytocin will be assessed as a treatment for ASD in adults with high functioning autism or Asperger's syndrome. The effect of oxytocin vs. placebo will be assessed using measures of social cognition, repetitive behaviors, irritability, and anxiety. This study will also employ event related recordings to collect naturalistic data on some of the above symptom areas. An additional part of this study will examine the effects of oxytocin on gene expression. Project Status


Funder National Institutes of Health
Fiscal Year Funding $2,202.00
Project Number 5M01RR000071-46
Principal Investigator Anagnostou, Athanasius
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4LA. Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014. IACC Recommended Budget: $22,200,000 over 5 years.
Federal or Private? Federal
Institution Mount Sinai School of Medicine
State/Country New York
Web Link 1 Intransal oxytocin in the treatment of autism (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
History/Related Projects Intransal oxytocin in the treatment of autism | $13,127.00 | 2008 | M01RR000071-45